



AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method for treating a ~~CNS disorder associated with impaired prefrontal-cortical-function~~ bipolar disorder or a working memory deficit in a subject comprising administering to said subject in need thereof an effective amount of a pharmaceutical composition comprising a ~~compound~~ chelerythrine or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof, ~~according to the structure:~~



(I)

or



(II)

wherein:

R^1 and R^2 are independently selected from H, C_1 - C_3 alkyl, F, Cl, Br, I, OH, $O(C_1$ - C_6 alkyl), $O-C(=O)-(C_1$ - $C_6)$ alkyl or $C(=O)-O-(C_1$ - $C_6)$ alkyl;

R^3 is H or a C_1 - C_6 alkyl group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently selected from H, C_1 - C_6 alkyl, F, Cl, Br, I, OH, $-(CH_2)_nO(C_1$ - C_6 alkyl), $-(CH_2)_nO-C(=O)-(C_1$ - $C_6)$ alkyl or $-(CH_2)_nC(=O)-O-(C_1$ - $C_6)$ alkyl;

R^9 and R^{10} are independently H, C_1 - C_6 alkyl or together form a $-(CH_2)_m-$ group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and A^- is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2 - 3. (Canceled)

4. (Currently Amended) A method of claim 1, ~~wherein the CNS disorder is a~~ for treating bipolar disorder.

5 - 9. (Canceled) A method of claim 1, wherein the CNS disorder is an anxiety disorder.

10. (Currently Amended) A method of claim 1, for treating a working memory deficit wherein the ~~CNS disorder is associated with enhanced PKC activity.~~

11. (Canceled)

12. (Original) A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.


13. (Canceled)

14. (Original) A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.


15.-17. (Canceled)

18. (Currently Amended) A method of treatment comprising administering to a subject suffering from manic episodes associated with enhanced PKC activity a therapeutically effective amount of chelerythrine or a pharmaceutically acceptable salt, solvate or polymorph thereof.

a composition containing a compound of the formula of the structure:



(I)



(II)

or

wherein:

R¹ and R² are independently selected from H, C₁-C₃alkyl, F, Cl, Br, I, OH, O(C₁-C₆alkyl), O-C(=O)-(C₁-C₆)alkyl or C(=O)-O-(C₁-C₆)alkyl;

R³ is H or a C₁-C₆alkyl group;

R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, C₁-C₆alkyl, F, Cl, Br, I, OH, -(CH₂)_nO(C₁-C₆alkyl), -(CH₂)_nO-C(=O)-(C₁-C₆)alkyl or -(CH₂)_nC(=O)-O-(C₁-C₆)alkyl;

R⁹ and R¹⁰ are independently H, C₁-C₆alkyl or together form a -(CH₂)_m- group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and A⁻ is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

19. (Original) A method of claim 18, wherein the manic episodes are also stress induced.

20. (Previously Presented) A method for preventing manic episodes in a bipolar patient comprising administering to the subject a therapeutically effective amount of a chelerythrine.

21. (Canceled)